Startup · $29.9m raised
Baltimore
Every investor coverage indicates participated in a round Glyscend raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon Capital | Series A | - |
| Brandon Capital Partners | Series A | - |
| Breakout Labs | Series A | - |
| Medical Research Commercialisation Fund (MRCF) | Series A | - |
| Santé Ventures | Series A | - |
Investors whose own portfolio pages list Glyscend, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon BioCatalyst | its portfolio page ↗ |
Companies Glyscend acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Glyscend. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Glyscend reports encouraging Phase 1 biomarker data for its diabetes drug GLY-200, announces US FDA clearance of its investigational new drug application, and has begun enrolling patients in a Phase 2 trial.
Biotech Glyscend reports its Phase 1 trial of GLY-200 for type 2 diabetes completed safely, and appoints Mark Fineman as Chief Development Officer ahead of a planned US regulatory filing and Phase 2 work.
Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.
Adelaide-backed biotech Glyscend is recruiting volunteers for phase 1 trials of a pill mimicking gastric bypass surgery to treat type 2 diabetes, funded with $29 million from Brandon Capital's MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio
Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio